Gismo Therapeutics Inc. is a biotech start-up company targeting invetsigation of the fundamental biochemical processes that are at the root of Alzheimers and Parkinsons Disease pathogenesis. Organized around a new hypothesis of the etiology of major neurodegenerative amyloid diseases,Gismo Therapeutics Inc. is developing first-in-class, disease modifying oral therapeutics for the treatment of both Alzheimers Disease and Parkinsons Disease. Previously located in New York state, the firm has shifted operations to Lexington, KY with the assistance of the Bluegrass Business Development Partnership made up of the University of Kentucky, Commerce Lexington and Lexington-Fayette Urban County Government.
